Cardiovascular Effects of Combined Administration of Siponimod and Propranolol - Importance of Sequencing During Co -administration

Trial Profile

Cardiovascular Effects of Combined Administration of Siponimod and Propranolol - Importance of Sequencing During Co -administration

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Siponimod (Primary) ; Propranolol
  • Indications Cardiovascular disorders; Multiple sclerosis
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 29 Apr 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 29 Apr 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 24 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top